Risk of acute arterial and venous thromboembolic events in Eosinophilic

Granulomatosis with Polyangiitis (Churg-Strauss syndrome)

Alessandra Bettiol[1,2#], PhD, Renato Alberto Sinico[3], MD, Franco Schiavon[4], MD, Sara Monti[5,6], Enrica Paola Bozzolo[7], MD, Franco Franceschini[8], MD, Marcello Govoni[9,10], MD, Claudio Lunardi[11], MD, Giuseppe Guida[12], MD, Giuseppe Lopalco[13], MD, Giuseppe Paolazzi[14], MD, Angelo Vacca[15], MD, Gina Gregorini[16], MD, Pietro Leccese[17], MD, Matteo Piga[18], MD, Fabrizio Conti[19], MD, Paolo Fraticelli[20], MD, Luca Quartuccio[21], MD, Federico Alberici[22], MD, Carlo Salvarani[23], MD, Silvano Bettio[24], MD, Simone Negrini[25,26], MD, PhD, Carlo Selmi[27,28], MD, Savino Sciascia[29,30], MD, Gabriella Moroni[31], MD, Loredana Colla[32], MD, Carlo Manno[33], MD, Maria Letizia Urban[1], MD, Alfredo Vannacci[2], MD, Maria Rosa Pozzi[3], MD, Paolo Fabbrini[34], MD, Stefano Polti[3], MD, Mara Felicetti[4], MD, Maria Rita Marchi[35], MD, Roberto Padoan[4], MD, Paolo Delvino[5,6], MD, Roberto Caporali[36,37], MD, Carlomaurizio Montecucco[5], MD, Lorenzo Dagna[7, 38], MD, Adriana Cariddi[7], MD, Paola Toniati[8], MD, Silvia Tamanini[8], MD, Federica Furini[9,10], MD, Alessandra Bortoluzzi[9,10], MD, Elisa Tinazzi[11], MD, Lorenzo Delfino[11], MD, Iuliana Badiu[12], MD, Giovanni Rolla[39], MD, Vincenzo Venerito[13], MD, Florenzo Iannone[13], MD, Alvise Berti[14], MD, Roberto Bortolotti[14], MD, Vito Racanelli[15], MD, Guido Jeannin[16], MD, Angela Padula[17], MD, Alberto Cauli[18], MD, Roberta Priori[19], MD, Armando Gabrielli[40], MD, Milena Bond[14,21], MD, Martina Tedesco[16,41], MD, Giulia Pazzola[23], MD, Paola Tomietto[24], MD, Marco Pellecchio[42], MD, Chiara Marvisi[23,43], MD, Federica Maritati[44], MD, Alessandra Palmisano[43], MD, Christian Dejaco[45,46], PhD, Johann Willeit[47], MD, Stefan Kiechl[47], MD, Iacopo

Olivotto[1,48], MD, PhD, Peter Willeit[47,49]*, PhD, Domenico Prisco[1]*, MD, Augusto

Vaglio[50,51]*, PhD, Giacomo Emmi[1]*, PhD, *on behalf of the Italian EGPA Consortium***.

*These authors contributed equally to this manuscript

#Corresponding author

Affiliations

1. Department of Experimental and Clinical Medicine, University of Firenze, Italy

2. Department of Neurosciences, Psychology, Drug Research and Child Health
   (NEUROFARBA), University of Firenze, Italy

3. Department of Medicine and Surgery, University of Milano – Bicocca and Nephrology
   Unit, ASST-Monza, Milan/Monza, Italy

4. Operative Unit of Rheumatology, Department of Medicine DIMED, University Hospital
   of Padova, Italy

5. Division of Rheumatology IRCCS Policlinico S.Matteo Foundation and University of
   Pavia, Pavia, Italy

6. University of Pavia, PhD in Experimental Medicine, Pavia, Italy.

7. Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), IRCCS-San
   Raffaele Scientific Institute, Milan, Italy

8. Unit of Rheumatology and Clinical Immunology, University and ASST Spedali Civili,
   Brescia, Italy

9. Department of Medical Sciences, University of Ferrara, Italy

10. Rheumatology Unit - Azienda Ospedaliero-Universitaria S. Anna - Ferrara (Cona)

11. Department of Medicine, University of Verona, Verona, Italy

12. Allergy and Pneumology Unit, A.O. S. Croce e Carle, Cuneo, Italy

13. Rheumatology Unit, Department of Emergency and Organ Transplantation (DETO), Polyclinic Hospital, University of Bari, Italy

14. Department of Rheumatology, Santa Chiara Hospital, Trento, Italy

15. Department of Biomedical Sciences and Human Oncology, Unit of Internal Medicine "Guido Baccelli", University of Bari "Aldo Moro" Medical School, Bari, Italy

16. Nephrology Unit, ASST Spedali Civili, Brescia, Italy

17. Rheumatology Department of Lucania - San Carlo Hospital, Potenza, Italy

18. Rheumatology, Department of Medical Sciences and Public Health, University Clinic, Cagliari, Italy

19. Rheumatology Unit, Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy

20. Department of Internal Medicine, Clinica Medica, Ospedali Riuniti, Ancona

21. Rheumatology Clinic, Department of Medicine (DAME), University of Udine, Udine, Italy

22. Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy; Nephrology Unit, Spedali Civili Hospital, Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, Brescia, Italy

23. Azienda USL-IRCCS di Reggio Emilia and University of Modena and Reggio Emilia

24. Rheumatology Unit, Internal Medicine Department, Cattinara Teaching Hospital (ASUITS) Trieste

25. Internal Medicine, Clinical Immunology and Translational Medicine Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy

26. Centre of Excellence for Biomedical Research and Department of Internal Medicine, University of Genoa, Genoa, Italy

27. Division of Rheumatology and Clinical Immunology, Humanitas Clinical and Research Center IRCCS, Rozzano - Milan, Italy

28. Department of Biomedical Sciences, Humanitas University, Pieve Emanuele - Milan, Italy

29. Center of Research of Immunopathology and Rare Diseases- Coordinating Center of the Network for Rare Diseases of Piedmont and Aosta Valley, Department of Clinical and Biological Sciences, University of Turin, Italy

30. SCU Nephrology and Dialysis, S. Giovanni Bosco Hospital, Department of Clinical and Biological Sciences, University of Turin, Italy

31. Nephrology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy

32. Nephrology, Dialysis and Renal Transplant Division, Department of Medical Sciences, "Città della Salute e della Scienza di Torino" University Hospital, University of Turin, Italy

33. Department of Emergency and Organ Transplantation, Nephrology, Dialysis and Transplant Unit, University of Bari "Aldo Moro", Bari, Italy.

34. Nephrology Unit, Hospital San Gerardo Monza, University of Milano Bicocca

35. Respiratory Pathophysiology Division, University Hospital of Padova, Italy

36. Division of Clinical Rheumatology, ASST Gaetano Pini-CTO Institute, Milan, Italy.

37. Department of Clinical Sciences & Community Health, Research Center for Adult and Pediatric Rheumatic Diseases, Università degli Studi di Milano, Milan, Italy.

38. Vita-Salute San Raffaele University, Milan, Italy

39. Department of Medical Science, Allergy and Clinical Immunology, University of Torino and AO Ordine Mauriziano Umberto I, Turin, Italy

40. Department of Internal Medicine, Università Politecnica delle Marche, Ancona, Italy

41. Department of Biomedical and Clinical Sciences "L. Sacco," University of Milan, Milan - Italy

42. Struttura Complessa Medicina Interna 1 P.O. Levante - ASL 2 Savona Liguria

43. Nephrology Unit, University Hospital, Parma, Italy

44. Department of Experimental Diagnostic and Specialty Medicine (DIMES), Nephrology, Dialysis and Renal Transplant Unit, St. Orsola Hospital, University of Bologna, Bologna, Italy

45. Hospital of Brunico (SABES-ASDAA), Department of Rheumatology, Brunico, Italy,

46. Department of Rheumatology and Immunology, Medical University Graz, Graz, Austria

47. Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria

48. Cardiomyopathy Unit, Careggi University Hospital, Florence, Italy.

49. Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK

50. Nephrology and Dialysis Unit, Meyer Children's Hospital, Florence, Italy

51. Department of Experimental, Clinical and Biomedical Sciences "Mario Serio", University of Firenze, Florence, Italy

[#]**Address for correspondence:**

Alessandra Bettiol, MSc PhD,

Department of Experimental and Clinical Medicine, University of Firenze

Largo Brambilla 3, 50134 Firenze, ITALY

Phone: +393400844273

e-mail: alessandra.bettiol@unifi.it

Conflict of interest statement: Dr. Silvia Tamanini worked at ASST Spedali Civili Brescia, Unit of Rheumatology and Immunology at the moment of the study. At the moment of publication, she works at Glaxo Smith Kline. All other authors report no conflicts of interest.

Funding: This study was not funded.

ABSTRACT

Background and objective: Systemic small vessel vasculitides carry an increased risk of acute arterial and venous thromboembolic events (AVTE); however, this risk has not been systematically explored in Eosinophilic Granulomatosis with Polyangiitis (EGPA).

This study assessed the occurrence and main risk factors of AVTE among EGPA patients as compared to the general community from the population-based Bruneck cohort.

Methods: We conducted a retrospective multicenter cohort study on 573 EGPA patients. Clinical and serological data were collected at diagnosis. Occurrence of AVTE and time to the first AVTE after EGPA diagnosis were recorded. Age-standardized event rate (SER) of AVTE as compared to the reference cohort was assessed. Cox regression was applied to identify AVTE predictors.

Results: 129 EGPA patients (22.5%) had AVTE, considered as potentially life-threatening in 55.8%. Seventy patients experienced an AVTE prior to diagnosis (of whom 58.6% in the two years before diagnosis) and 75 following EGPA diagnosis, of whom 56% in the two subsequent years. The SER of AVTE as compared to the reference cohort was 2.10 (95% CI 1.67-2.63). This risk was particularly increased in patients with history of AVTE and with a Birmingham Vasculitis Activity Score ≥20 at diagnosis. Patients receiving immunosuppression within 2 months of diagnosis were at lower risk, while antiplatelet or anticoagulant treatment did not confer measurable benefit.

Conclusion: EGPA is associated with AVTE in approximately one quarter of patients, particularly around diagnosis. Immunosuppressants seemed to exert a protective effect, while anticoagulant and antiplatelet agents did not.

INTRODUCTION

Eosinophilic Granulomatosis with Polyangiitis (EGPA, Churg-Strauss syndrome) belongs to the anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAVs), which also include Granulomatosis with Polyangiitis and Microscopic Polyangiitis[1, 2]. An increased frequency of vascular events due to the involvement of medium-sized and large vessels has been reported consistently in AAV[3–5]. Recent evidence indicates an association between disease activity and thrombotic risk in AAV regardless of clinical diagnosis or ANCA specificity, suggesting that vascular inflammation *per se* is a major determinant of thrombosis [6, 7].

EGPA is characterized by eosinophilic vasculitis and eosinophil-rich extravascular inflammation and typically presents with peripheral eosinophilia[8, 9]. Cardiac manifestations are reported in 40-60% of patients, and represent the leading cause of mortality[10, 11]. Recent reports suggest that acute arterial and venous thromboembolic events (AVTE) might represent a consistent burden of disease in EGPA patients[5], possibly due to vascular inflammation or to cardio-embolic events secondary to EGPA-related cardiomyopathy. Additionally, eosinophilia is a major determinant of thrombosis, as suggested by the notion that different eosinophilic conditions show a high prevalence of AVTE [12].

In the present study, we assessed incidence, type and timing of AVTEs in the largest EGPA cohort reported thus far, and compared incidence estimates with those in the general community obtained from the population-based Bruneck study cohort, and identified independent predictors of risk. We considered AVTEs that occurred both before and after EGPA diagnosis, and analyzed possible associations between AVTE, disease activity, other disease-related parameters and pharmacological treatments including anticoagulant and antiplatelet agents.

MATERIALS AND METHODS

Study design and setting

We conducted a retrospective observational cohort study. The study involved 28 Italian

EGPA referral centres, including rheumatology, nephrology, clinical immunology,

pulmonology and internal medicine units. It was conducted in compliance with the

Declaration of Helsinki and approved by the Ethic Committee of the University Hospital

Careggi, Florence, Italy (Approval number 12804/CAM_BIO).

Participants

We consecutively included all EGPA patients followed between January 1988 and September

2018. The patients' demographic, serological and clinical data were retrieved from medical

charts and recorded into an electronic database created *ad hoc* for the study. All patients had

to fulfil the American College of Rheumatology classification criteria for EGPA [13] or the

criteria proposed in the MIRRA trial [14].

Exposure and outcome variables

The following demographic and clinical data were collected at the time of EGPA diagnosis:

age, gender, previous AVTEs and presence of cardiovascular risk factors and/or comorbidities

(including smoking habit, hypercholesterolemia, hypertension, diabetes mellitus, and history

of cancer) and ongoing cardiovascular therapies.

EGPA-related clinical and serological data at diagnosis were recorded, including specific

organ manifestations, disease activity based on the Birmingham Vasculitis Activity Score

(BVAS)[15], presence of ANCA, and laboratory tests including C-reactive protein,

erythrocyte sedimentation rate, eosinophil count, eosinophil cationic protein, IgG4 and IgE

titers. For each patient, the revised five-factor score was calculated [16], with one point each

attributed to the following factors: cardiac, gastrointestinal or renal involvement; age >65 years; absence of ear-nose-throat involvement.

The immunosuppressive treatments started after diagnosis were also recorded.

After EGPA diagnosis, we recorded the first AVTE and the time of occurrence.

AVTE were classified as arterial or venous. Namely, venous events included deep venous thrombosis (DVT), pulmonary embolism, superficial venous thrombosis (SVT), and thrombosis at atypical locations, including ovarian, renal, splanchnic, jugular, retinal vein occlusion, and cerebral venous sinus thrombosis[17]. Arterial events included acute myocardial infarction, stroke, transient ischemic attack, acute ischemia of the upper and lower limbs, and arterial retinal occlusion.

Events related to acute myocardial infarction, stroke or pulmonary embolism were considered as potentially life-threatening.

For each patient, we calculated the accumulated person-time (person-years) as to the time elapsed from diagnosis until the first AVTE (when present) or the end of the follow-up.

AVTE in the reference cohort

AVTE rates in EGPA patients where compared with those in the general population, using data from the Bruneck Study as a reference. The Bruneck Study is a prospective population-based study located in Northern Italy[18, 19]. In ascertaining AVTE outcomes, the participants' self-reported medical history was carefully reviewed together with the medical records provided by general practitioners, Bruneck Hospital databases and death certificates. As in the EGPA cohort, time-to-event data in the Bruneck cohort was censored at the date of the first event, death, or end of follow-up, whichever was the earliest.

Statistical analysis

No statistical sample size calculation was performed *a priori*.

Continuous variables are presented as median (interquartile range- IQR), while categorical variables as n (%).

Standardized event ratios (SERs) of AVTE in the EGPA cohort as compared to the reference Bruneck cohort were calculated. Time-to-event data of the Bruneck and EGPA cohorts were split by categories of age (i.e. <55 years, 55 to <65 years, 65 to <75 years, and ≥75 years) and the observed number of events in the EGPA cohort was compared to the expected event number if age-specific event rates had been identical to the Bruneck cohort. The 95% confidence intervals (CI) of the SERs were calculated as described by Rothman and Greenland [20].

Within the EGPA cohort, the risk of AVTE was estimated by fitting Cox regression models to calculate hazard ratios (HR) and related 95% CI and to derive Kaplan-Meier curves of AVTE. Covariates for model adjustments were selected from three areas: i) demographic characteristics (age, sex); ii) cardiovascular risk factors (previous AVTE, traditional atherogenic risk factors); and iii) EGPA-related variables (ANCA, BVAS, and eosinophils). To assess the robustness of our findings, a sensitivity analysis was performed excluding patients with history of AVTE prior to EGPA diagnosis. The analyses were performed using the software STATA version 14. Statistical significance was considered for p values <0.05.

RESULTS

A total of 573 EGPA patients were included in the study. The main features recorded at time of EGPA diagnosis are described in **Table 1**. 297 patients (51.8%) were women; the median age at EGPA diagnosis was 55.3 years (IQR 44.8–64.0). Hypertension was the most frequent cardiovascular risk factor, followed by hypercholesterolemia. Regarding cardioprotective therapy, antihypertensive agents were the most employed drugs, followed by antiplatelet agents and statins. The most common EGPA manifestations included lower respiratory tract

involvement (96.3%), ear-nose-throat involvement (79.4%), and peripheral neuropathy (63.2%). The median BVAS score at diagnosis was 12 (7-18); 130 patients had a five-factor score of zero, whereas 443 had a five-factor score ≥1. The results of ANCA testing were available for 485 patients. Of them, 243 (50.1%) were classified as ANCA-positive: 224 were ANCA-positive by IF, with most being positive for P-ANCA. Using ELISA, 215 patients were ANCA-positive; anti-myeloperoxidase (MPO) and anti-proteinase 3 (PR3) antibodies were respectively detected in 200 and 15 of them. Considering other laboratory parameters, the median values of C-reactive protein, erythrocyte sedimentation rate, eosinophil count and eosinophil cationic protein were respectively 5.2 mg/dL (2.1–10.4), 42.5 mm/h (23.0-61.0), 2680 U/mmc (1094.3–7600.0), and 52.0 µg/L (17.0–135.0). The median IgG4 level was 250.0 mg/dL (97.0–558.0), and the median IgE 400.0 U/mL (169.0–1000.0).

After diagnosis, most patients (301, 52.5%) received traditional or biologic immunosuppressive agents, while only 44.4% were treated with systemic glucocorticoids alone. Only 2.8% of all patients did not receive immunosuppressive therapy within two months of diagnosis (including 1.6% who received delayed treatment, while 1.2% never received immunosuppression).

AVTE occurrence and age-standardized rates

Overall, 129 EGPA patients (22.5%) had AVTE, including 70 (12%) prior to diagnosis and 75 (13%) following the diagnosis of EGPA [median follow-up 1677 days (IQR 663–3137)]. AVTE prior to EGPA diagnosis. Of the 70 patients who experienced AVTE before EGPA diagnosis (**Figure 1**), most did within the previous two years (n=41; 58%). Specifically, arterial events had occurred in 47 patients, whereas 18 patients had developed venous events and/or pulmonary embolism. In the remaining 5 patients, no information regarding the type of

AVTE was available. Five patients had experienced two AVTEs each before diagnosis (both

venous in two patients, both arterial in one, and one venous and one arterial in two.

AVTE after EGPA diagnosis. After a median follow-up of 1677 days (IQR 663–3137)

following EGPA diagnosis, 75 patients (13.1%) experienced at least one AVTE; the median

time from the diagnosis of EGPA to the first AVTE was 577 days (IQR 81–2100). Ten events

occurred at time of EGPA diagnosis, leading or contributing to identification of the

underlying disease. Overall, forty-two out of the 75 events (56.0%) occurred in the two years

following diagnosis (**Figure 1**), and >80% within the first six years. **Figure 2** shows the

cumulative probability of a first AVTE after diagnosis in the whole cohort of patients.

Thirty-two of these first AVTE were venous (19 DVT, 5 pulmonary embolism, 3 SVT, and 5

thrombosis at atypical locations, the latter including 2 Budd-Chiari syndromes, 2 retinal vein

occlusions, 1 intracardiac thrombosis), whereas the remaining 43 were arterial (23 acute

myocardial infarction, 10 stroke, 7 transient ischemic attack, 1 retinal artery occlusion, 1 acute

upper limb ischemia, and 1 acute lower limb ischemia) (**Supplementary figure 1**).

No information on the clinical prognosis and outcome following AVTE was available;

however, 72/129 patients (55.9%) experienced events considered as potentially life-

threatening (i.e., related to acute myocardial infarction, stroke, or pulmonary embolism).

Age-standardized AVTE rates were calculated using a reference cohort of 933 individuals

from the Bruneck Study (**Supplementary table 1**). In this reference cohort, 280 AVTE (226

arterial and 54 venous) were observed after a median follow-up of 20.9 years (10.3-25.6).

Details on the observed AVTE are described in the **Supplementary table 2**.

The age-SER in EGPA patients as compared to the reference cohort was 2.10 (1.67-2.63;

p<0.001) (**Table 2**). The highest SERs were observed for patients aged 55-65 years [3.24

(2.16-4.88)] or younger than 55 [3.12 (2.11-4.62)]. When stratifying the analysis according to

the type of event, a SER of 1.64 (1.22-2.22) was found for arterial events (p<0.001); this rate was higher in EGPA patients younger than 65 years. With respect to venous events, the SER was 3.32 (2.35-4.70) (p<0.001); this increased risk in the EGPA cohort was statistically significant in all age classes.

AVTE predictors after EGPA diagnosis

Figure 3a shows adjusted HRs of AVTE based on different demographic and clinical features recorded at diagnosis. A significantly higher risk of AVTE was found in patients with a history of previous AVTE (HR 2.06 [95%CI 1.15-3.67], p=0.015) and in patients with BVAS ≥ 20 at diagnosis [HR 2.02 (95%CI 1.03–3.96) as compared with patients with BVAS 0-9, p=0.041], while no association was found between the five-factor score and the development of AVTE. Furthermore, no association was found with ANCA positivity, sex, age at diagnosis and presence of classic cardiovascular risk factors. Of note, the association between BVAS and AVTE was confirmed also when limiting the analyses to patients with no history of AVTE before EGPA diagnosis (**Supplementary table 3**). On the other hand, baseline levels of eosinophils as well as of C-reactive protein, erythrocyte sedimentation rate, IgG4 and IgE levels did not influence the risk of AVTE (data not shown). The influence of eosinophil cationic protein levels on the risk of AVTE was not assessed, due to the high proportion of missing data.

Regarding disease manifestations (**Figure 3b**), a slightly higher, but of borderline statistical significance, risk of AVTE was found for patients with ear-nose-throat or cardiac involvement [HR 1.98 (95%CI 0.99–3.92]) and 1.65 (95%CI 0.97-2.82), respectively], whereas renal involvement was associated with a lower risk of AVTE [HR 0.38 (95%CI 0.17–0.86), p=0.020]. None of the other clinical manifestations significantly influenced the risk of AVTE.

Pharmacological treatments and AVTE occurrence

We finally investigated the role of immunosuppressive and cardiovascular therapy at EGPA

diagnosis on the risk of AVTE occurrence. The 16 patients who did not receive any

immunomodulating therapy within the first two months of diagnosis had a significantly higher

risk of AVTE as compared with patients receiving systemic glucocorticoids [HR 3.67 (1.37–

9.89), p=0.010], whereas risk was comparable in patients treated with immunosuppressants as

compared with systemic glucocorticoids alone (data not shown). Of note, the association

between the lack of immunosuppression within 2 months of diagnosis and risk of AVTE was

confirmed also when considering only patients with no history of AVTE prior to EGPA

diagnosis (data not shown).

With respect to the ongoing cardioprotective treatments at the time of diagnosis, no

association was found between antiplatelet, anticoagulant or statin therapy and the risk of

AVTE (adjusted HR of 0.99 [95%CI 0.98–1.01], p=0.985 for antiplatelets, 0.35 [95%CI 0.09–

1.57], p=0.176 for anticoagulants, and 0.96 [95%CI 0.40–2.26], p=0.918 for statins).

DISCUSSION

In the present study, presenting the largest EGPA cohort reported to date, we observed a

significant increase in age standardized risk of arterial and venous acute thromboembolic

events associated with the disease compared to the general population. Overall, 23% of 573

patients developed AVTE, both prior and following the diagnosis of EGPA, half of them

being potentially life threatening and representing the reason for initial diagnosis of the

underlying disease in 10 cases.

Notably, the majority of these events clustered in the two years before and the two years after the diagnosis and peaked in the periods of highest disease activity. Conversely, classic cardiovascular risk factors had no impact on risk and, specifically, EGPA was associated with increased rates of arterial events compared to the reference population in spite of a more favorable cardiovascular risk profile.

The fact that active inflammation, rather than traditional mechanisms of thrombosis, promotes AVTE in EGPA, is strongly supported by the observed effects of treatment. The small subset of patients who did not receive systemic glucocorticoids or immunosuppressants during the first two months after EGPA diagnosis were at distinctively greater risk of AVTEs compared to treated patients. Conversely, lack of both anticoagulant and antiplatelet agent use did not seem to confer any added risk. These findings lend further support to the view that AVTEs are directly determined by active EGPA vascular involvement, and may be prevented by adequate and timely immunosuppression[21–23]. Although these findings may also reflect the fact that anticoagulant/antiplatelet agents are more likely prescribed to the most severe patients, thus representing a bias in our analysis, these novel observations warrant further investigation in the field.

The results of the present study are consistent with the notion that EGPA evolves through different phases, namely an allergic phase which usually lasts for years, a eosinophilic phase of shorter duration, and a rapidly evolving vasculitic phase[1]. This sequence of disease stages suggests that eosinophilic inflammation is already active before the full-blown disease manifestations develop and may play a decisive role in the development of AVTEs soon before and after the initial diagnosis, plausibly as a reflection of uncontrolled active disease. Indeed, we found that patients younger than 65 years had the highest SER of AVTE. Considering that in our cohort around 75% of patients were diagnoses at <65 years of age,

this result further corroborates our hypothesis that the high disease activity around diagnosis probably influences the AVTE risk.

In our cohort, the majority of AVTEs were arterial and mainly included acute myocardial infarction and stroke. Most published studies focused on the association between AAVs and venous thromboembolism[5, 6, 23], while limited evidence supports an association with arterial manifestations[3, 4, 24]. Venous thromboembolic events, although less frequent than arterial events, were associated with the highest SER as compared to the reference population. As expected, most were lower limb DVT or pulmonary embolism, although a few patients developed thrombosis at atypical sites. In a retrospective analysis of the French Vasculitis Study Group including 232 EGPA patients, 8.2% developed venous thromboembolic events after a mean follow-up of 58 months. Interestingly, most events occurred between 3 months before and 6 months after diagnosis[6]. A Russian study including 69 EGPA cases reported that 5 of them (7.2%) developed venous thromboembolism, all during the first year after diagnosis[25]. With regard to the other AAVs, a particular increase in risk of DVT[7, 26] and pulmonary embolism [7] was observed during active disease[27].

Finally, we identified several predictors on AVTE in EGPA. Patients who had experienced AVTEs before diagnosis were at higher risk of developing additional events following diagnosis, likely related to pre-existing vascular injury and individual susceptibility[28]. This, close clinical monitoring is required in secondary prevention for these patients[6, 26]. Furthermore, while ear-nose-throat and cardiac manifestations seemed associated with an increased risk of AVTE, renal involvement did not. Whether these discrepancies reflect the diverse biology of the two main clinical subsets of EGPA, *i.e.* vasculitic vs eosinophilic (with the latter being more prone to AVTE), is unclear. The lack of association between ANCA status and AVTE does not seem to corroborate this hypothesis.

Our study has other limitations, some of which are inherent to retrospective studies. First, as AVTEs diagnoses were retrospectively captured from medical charts, misclassification of the events might have occurred. Second, the role of some heterogeneity in clinical management due to the long-term study period cannot be excluded. Finally, no information on the clinical prognosis and outcome following AVTE was available. Despite these limitations, our study finds its strengths in its large sample size, the long follow-up, and the presence of a reference population.

In conclusion, our results show a higher risk of both acute AVTE events in patients with EGPA as compared to a reference population, particularly around the time of EGPA diagnosis and in those without immunosuppressive treatments. Notably, the occurrence of venous events was stably high throughout the whole duration of the disease, suggesting the need of a close and long-term monitoring particularly for such events. Based on our data EGPA seems to represent a cardiovascular risk factor independently from the patient's demographic and clinical features, and AVTE risk is particularly increased in patients with previous AVTE and high disease activity. These findings also suggest that the occurrence of unexplained AVTE in healthy subjects should be investigated in order to exclude an underlying eosinophilic condition, and particularly EGPA.

ACKNOWLEDGEMENTS

All people who contributed to this manuscript are listed as authors or collaborators.

**Collaborators of the EGPA Italian Consortium:

Elena Bargagli (Department of Medicine, Surgery and Neurosciences, Respiratory Diseases and Lung Transplantation, Regional Referral Centre for Sarcoidosis and ILD, Siena University, Siena), Matteo Becatti (Department of Experimental and Clinical Biomedical

Sciences "Mario Serio", University of Firenze, Firenze, Italy), Mirko Beccalli (Internal Medicine, Clinical Immunology and Translational Medicine Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy), Federica Bello (Department of Experimental and Clinical Medicine, University of Firenze, Italy), Francesco Bozzao (Rheumatology Unit, Medicina Clinica, Cattinara Teaching Hospital (ASUITS) Trieste)), Valentina Canti (Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), IRCCS-San Raffaele Scientific Institute, Milan, Italy), Matthias A. Cassia (ASST Santi Paolo e Carlo and the University of Milan, Milan, Italy), Giulia Cassone (Clinical and Experimental Medicine PhD Program, Azienda USL-IRCCS di Reggio Emilia and Università di Modena and Reggio Emilia, Italy), Mariagrazia Catanoso (Rheumatology Unit, Department of Specialistic Medicine, Azienda USL-IRCCS di Reggio Emilia, Italy), Fulvia Chieco-Bianchi (Respiratory Pathophysiology Division, University Hospital of Padova, Italy), Roberta Clari (Nephrology, Dialysis and Renal Transplant Division, Department of Medical Sciences, "Città della Salute e della Scienza di Torino" University Hospital, University of Turin, Italy), Laura Coladonato (Rheumatology Unit, Department of Emergency and Organ Transplantation (DETO), Polyclinic Hospital, University of Bari, Italy), Maria De Santis (Division of Rheumatology and Clinical Immunology, Humanitas Clinical and Research Center - IRCCS , Rozzano, Milan, Italy), Gerardo Di Scala (Department of Experimental and Clinical Medicine, University of Firenze, Italy), Filippo Fagni (Department of Experimental and Clinical Medicine, University of Firenze, Italy), Paride Fenaroli (Nephrology Unit, Parma University Hospital, Parma, Italy), Claudia Fiorillo (Department of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Firenze, Firenze, Italy), Alberto Floris (Rheumatology, Department of Medical Sciences and Public Health, Univerisity Clinic, Cagliari, Italy), Marco Fornaro (Rheumatology Unit, Department of Emergency and Organ Transplantation (DETO), Polyclinic Hospital, University of Bari, Italy), Elena Galli

(University of Modena and Reggio Emilia, Modena, Italy), MD, Elena Generali (Division of Rheumatology and Clinical Immunology, Humanitas Clinical and Research Center, IRCCS, Rozzano, Milan, Italy), Marica Giliberti (Department of Emergency and Organ Transplantation, Nephrology, Dialysis and Transplant Unit, University of Bari "Aldo Moro", Bari, Italy), Nancy Lascaro (Rheumatology Institute of Lucania (IRel) and the Rheumatology Department of Lucania, San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera, Potenza and Matera, Italy), Ilaria Leccese (Rheumatology Unit, Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy), Irene Mattioli (Department of Experimental and Clinical Medicine, University of Firenze, Italy) , Bianca Olivieri (Department of Medicine, Università degli Studi di Verona, Italy), Nicola Osti (Department of Medicine, Università degli Studi di Verona, Italy), Francesco Peyronel (Nephrology Unit, University Hospital, Parma, Italy), Massimo Radin (Department of Clinical and Biological Sciences, University of Turin, Italy), Giulia Righetti (Rheumatology Unit, Department of Emergency and Organ Transplantation (DETO), Polyclinic Hospital, University of Bari, Italy), Stefano Salvati (Vita-Salute San Raffaele University, Milan, Italy), Elena Silvestri (Department of Experimental and Clinical Medicine, University of Firenze, Italy), Nicola Susca (Department of Biomedical Sciences and Human Oncology, Unit of Internal Medicine "Guido Baccelli", University of Bari "Aldo Moro" Medical School, Bari, Italy), Carlo Tamburini (Department of Experimental and Clinical Medicine, University of Firenze, Italy; SOD Interdisciplinary Internal Medicine, Center for Autoimmune Systemic Diseases-Behçet Center and Lupus Clinic-AOU Careggi Hospital of Florence, Florence, Italy), Giusy Taurisano (Department of Experimental and Clinical Medicine, University of Firenze, Italy), Barbara Trezzi (Department of Medicine and Surgery, University of Milano – Bicocca and Nephrology Unit, ASST-Monza, Milan/Monza, Italy), Giorgio Trivioli (Nephrology and Dialysis Unit, Meyer Children's Hospital; Department of

Experimental and Clinical Biomedical Sciences "Mario Serio", University of Firenze, Firenze, Italy).

Alessandra Bettiol wrote the manuscript, assisted by Giacomo Emmi and Augusto Vaglio.

All authors and co-authors critically revised the manuscript, approved the final version of this manuscript, and agreed to be accountable for all aspects of the work, ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Conflict of interest statement: Dr. Silvia Tamanini worked at ASST Spedali Civili Brescia, Unit of Rheumatology and Immunology at the moment of the study. At the moment of publication, she works at Glaxo Smith Kline. All other authors report no conflicts of interest.

Financial support: This study was not funded.

REFERENCES

1.	Vaglio A, Buzio C, Zwerina J. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): state of the art. *Allergy* 2013; 68: 261–273.

2.	Vaglio A, Moosig F, Zwerina J. Churg–Strauss syndrome. *Curr. Opin. Rheumatol.* 2012; 24: 24–30.

3.	Morgan MD, Turnbull J, Selamet U, Kaur-Hayer M, Nightingale P, Ferro CJ, Savage COS, Harper L. Increased incidence of cardiovascular events in patients with antineutrophil cytoplasmic antibody-associated vasculitides: a matched-pair cohort study. *Arthritis Rheum.* 2009; 60: 3493–3500.

4.	Faurschou M, Mellemkjaer L, Sorensen IJ, Svalgaard Thomsen B, Dreyer L, Baslund B. Increased morbidity from ischemic heart disease in patients with Wegener's granulomatosis. *Arthritis Rheum.* 2009; 60: 1187–1192.

5.	Ames PRJ, Margaglione M, Mackie S, Alves JD. Eosinophilia and thrombophilia in churg strauss syndrome: a clinical and pathogenetic overview. *Clin. Appl. Thromb. Hemost.* 2010; 16: 628–636.

6.	Allenbach Y, Seror R, Pagnoux C, Teixeira L, Guilpain P, Guillevin L, French Vasculitis Study Group. High frequency of venous thromboembolic events in Churg-Strauss syndrome, Wegener's granulomatosis and microscopic polyangiitis but not polyarteritis nodosa: a systematic retrospective study on 1130 patients. *Ann. Rheum. Dis.* 2009; 68: 564–567.

7.	Faurschou M, Obel N, Baslund B. High Risk of Pulmonary Embolism and Deep Venous Thrombosis but Not of Stroke in Granulomatosis With Polyangiitis (Wegener's). *Arthritis Care Res. (Hoboken).* 2014; 66: 1910–1914.

8.	Greco A, Rizzo MI, De Virgilio A, Gallo A, Fusconi M, Ruoppolo G, Altissimi G, De Vincentiis M. Churg–Strauss syndrome. *Autoimmun. Rev.* 2015; 14: 341–348.

9.   Sinico R, Di Toma L, Maggiore U, Bottero P, Radice A, Tosoni C, Grasselli C, Pavone
        L, Gregorini G, Monti S, Frassi F, Vecchio F, Corace C, Venegoni E, Buzio C.
        Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-
        Strauss syndrome. *Arthritis Rheum.* 2005; 52: 2926–2935.

10.   Dennert RM, van Paassen P, Schalla S, Kuznetsova T, Alzand BS, Staessen JA,
        Velthuis S, Crijns HJ, Tervaert JWC, Heymans S. Cardiac involvement in Churg-
        Strauss syndrome. *Arthritis Rheum.* 2010; 62: 627–634.

11.   Comarmond C, Pagnoux C, Khellaf M, Cordier J-F, Hamidou M, Viallard J-F, Maurier
        F, Jouneau S, Bienvenu B, Puéchal X, Aumaître O, Guenno G Le, Quellec A Le,
        Cevallos R, Fain O, Godeau B, Seror R, Dunogué B, Mahr A, Guilpain P, Cohen P,
        Aouba A, Mouthon L, Guillevin L. Eosinophilic granulomatosis with polyangiitis
        (Churg-Strauss): Clinical characteristics and long-term followup of the 383 patients
        enrolled in the French Vasculitis Study Group cohort. *Arthritis Rheum.* 2013; 65: 270–
        281.

12.   Maino A, Rossio R, Cugno M, Marzano A V, Tedeschi A. Hypereosinophilic
        syndrome, Churg-Strauss syndrome and parasitic diseases: possible links between
        eosinophilia and thrombosis. *Curr. Vasc. Pharmacol.* 2012; 10: 670–675.

13.   Masi AT, Hunder GG, Lie JT, Michel BA, Bloch DA, Arend WP, Calabrese LH,
        Edworthy SM, Fauci AS, Leavitt RY. The American College of Rheumatology 1990
        criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and
        angiitis). *Arthritis Rheum.* 1990; 33: 1094–1100.

14.   Wechsler ME, Akuthota P, Jayne D, Khoury P, Klion A, Langford CA, Merkel PA,
        Moosig F, Specks U, Cid MC, Luqmani R, Brown J, Mallett S, Philipson R, Yancey
        SW, Steinfeld J, Weller PF, Gleich GJ, EGPA Mepolizumab Study Team.
        Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. *N. Engl.*

J. Med. 2017; 376: 1921–1932.

15.   Mukhtyar C, Lee R, Brown D, Carruthers D, Dasgupta B, Dubey S, Flossmann O, Hall C, Hollywood J, Jayne D, Jones R, Lanyon P, Muir A, Scott D, Young L, Luqmani RA. Modification and validation of the Birmingham Vasculitis Activity Score (version 3). *Ann. Rheum. Dis.* 2009; 68: 1827–1832.

16.   Guillevin L, Pagnoux C, Seror R, Mahr A, Mouthon L, Le Toumelin P, French Vasculitis Study Group (FVSG). The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. *Medicine (Baltimore).* 2011; 90: 19–27.

17.   Janczak DT, Mimier MK, McBane RD, Kamath PS, Simmons BS, Bott-Kitslaar DM, Lenz CJ, Vargas ER, Hodge DO, Wysokinski WE. Rivaroxaban and Apixaban for Initial Treatment of Acute Venous Thromboembolism of Atypical Location. *Mayo Clin. Proc.* 2018; 93: 40–47.

18.   Kiechl S, Willeit J. In a Nutshell: Findings from the Bruneck Study. *Gerontology* 2019; 65: 9–19.

19.   Willeit P, Kiechl S, Kronenberg F, Witztum JL, Santer P, Mayr M, Xu Q, Mayr A, Willeit J, Tsimikas S. Discrimination and net reclassification of cardiovascular risk with lipoprotein(a): prospective 15-year outcomes in the Bruneck Study. *J. Am. Coll. Cardiol.* 2014; 64: 851–860.

20.   Rothman KJ, Greenland S. Modern Epidemiology, 2nd Edition. Lippincott Williams & Wilkins, editor. 1998.

21.   Emmi G, Vitale A, Silvestri E, Boddi M, Becatti M, Fiorillo C, Fabiani C, Frediani B, Emmi L, Di Scala G, Goldoni M, Bettiol A, Vaglio A, Cantarini L, Prisco D. Adalimumab-Based Treatment Versus Disease-Modifying Antirheumatic Drugs for Venous Thrombosis in Behçet's Syndrome: A Retrospective Study of Seventy Patients

With Vascular Involvement. *Arthritis Rheumatol. (Hoboken, N.J.)* 2018; 70: 1500–1507.

22. Becatti M, Emmi G, Silvestri E, Bruschi G, Ciucciarelli L, Squatrito D, Vaglio A, Taddei N, Abbate R, Emmi L, Goldoni M, Fiorillo C, Prisco D. Neutrophil Activation Promotes Fibrinogen Oxidation and Thrombus Formation in Behçet Disease. *Circulation* 2016; 133: 302–311.

23. Emmi G, Silvestri E, Squatrito D, Amedei A, Niccolai E, D'Elios MM, Della Bella C, Grassi A, Becatti M, Fiorillo C, Emmi L, Vaglio A, Prisco D. Thrombosis in vasculitis: from pathogenesis to treatment. *Thromb. J.* 2015; 13: 15.

24. Kang A, Antonelou M, Wong NL, Tanna A, Arulkumaran N, Tam FWK, Pusey CD. High Incidence of Arterial and Venous Thrombosis in Antineutrophil Cytoplasmic Antibody–associated Vasculitis. *J. Rheumatol.* 2018; 46(3):285-293.

25. Novikov P, Makarov E, Moiseev S, Meshkov A, Strizhakov L. Venous thromboembolic events in systemic vasculitis: Table 1. *Ann. Rheum. Dis.* 2015; 74: e27–e27.

26. Berti A, Matteson EL, Crowson CS, Specks U, Cornec D. Risk of Cardiovascular Disease and Venous Thromboembolism Among Patients With Incident ANCA-Associated Vasculitis: A 20-Year Population-Based Cohort Study. *Mayo Clin. Proc.* 2018; 93: 597–606.

27. Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. *N. Engl. J. Med.* 2005; 352: 351–361.

28. Abtan J, Bhatt DL, Elbez Y, Sorbets E, Eagle K, Ikeda Y, Wu D, Hanson ME, Hannachi H, Singhal PK, Steg PG, Ducrocq G, REACH Registry Investigators. Residual Ischemic Risk and Its Determinants in Patients With Previous Myocardial Infarction and Without Prior Stroke or TIA: Insights From the REACH Registry. *Clin.*

Cardiol. 2016; 39: 670–677.

TABLES

Table 1: Demographic characteristics, cardiovascular risk factors, cardioprotective therapy and EGPA-related features at time of EGPA diagnosis.

	N (%)
Demographic features	
Age at diagnosis (median (IQR))- years	55.30 (44.75 – 64.02)
Sex (n. obs. 573)	
Male	276 (48.17)
Female	297 (51.83)
Cardiovascular risk factors and comorbidities	
Smoking (n. obs. 519)	80 (15.41)
Others (n. obs. 573)	
Hypercholesterolemia	95 (16.58)
Hypertension	163 (28.45)
Diabetes mellitus	33 (5.76)
Cancer	53 (9.25)
Cardiovascular therapy (n. obs. 573)	
Antiplatelets	60 (10.47)
Anticoagulants	31 (5.41)
Antihypertensive agents	145 (25.31)
Statins	49 (8.55)
Disease manifestations (n. obs. 573)	
Lower respiratory tract	552 (96.34)
Ear-Nose-Throat	455 (79.41)
Peripheral neuropathy	362 (63.18)
Cutaneous	210 (36.65)
Constitutional	171 (29.84)
Cardiac	122 (21.29)
Renal	79 (13.79)
Gastrointestinal	58 (10.12)
Musculoskeletal	30 (5.24)
Ocular	4 (0.70)
Others	2 (0.35)
Disease activity (n. obs. 573)	
BVAS (median (IQR))	12 (7 – 18)
0-9	205 (35.78)
10-19	266 (46.62)
20+	102 (17.80)
Five-Factor Score	

0	130 (22.69)
≥ 1	443 (77.31)
ANCA (n. obs. 485)	
Negative	242 (49.90)
Positive	243 (50.10)
IF-ANCA (n. obs. 476)	
Negative	252 (52.94)
Positive	224 (47.06)
P-ANCA	213 (95.1)[#]
C-ANCA	11 (4.9)[#]
ELISA-ANCA (n. obs. 452)	
Negative	237 (52.4)
Positive	215 (47.6)
Anti-MPO	200 (93.0)[#]
Anti-PR3	15 (7.0)[#]
Laboratory parameters (median (IQR))	
C-reactive protein (n. obs. 373), mg/L	5.20 (2.14 – 10.40)
Erythrocyte sedimentation rate (n. obs. 354), mm/h	42.50 (23.00 - 61.00)
Eosinophils (n. obs. 459), U/mmc	2680.00 (1094.30 – 7600.00)
Eosinophil cationic protein (n. obs. 57) µg/L	52.00 (17.00 – 135.00)
IgG4 (n. obs. 58), mg/dL	250.00 (97.00 – 558.00)
IgE (n. obs. 143), U/mL	400.00 (169.00 – 1000.00)
Immunosuppressive therapy* (n. obs. 570)	
No systemic therapy	16 (2.80)
Only systemic glucocorticoids	253 (44.39)
Traditional and/or biologic immunosuppressants (+/- glucocorticoids)	301 (52.81)
Cyclophosphamide	165 (28.95)
Methotrexate	63 (11.05)
Azathioprine	56 (9.82)
Cyclosporine A	50 (8.77)
IVIg	20 (3.50)
Rituximab	7 (1.23)
Other biologic agents	7 (1.23)
Mycophenolate	6 (1.05)
Infliximab	2 (0.35)
Omalizumab	2 (0.35)
Mepolizumab	1 (0.18)

*within two months from EGPA diagnosis

[#]% out of the total number of patients with positivity

ANCA: Anti-Neutrophil Cytoplasmic Antibody; BVAS: Birmingham Vasculitis Activity Score;

EGPA: Eosinophilic Granulomatosis with Polyangiitis; IQR: Interquartile range; MPO:

Myeloperoxidase; PR3: Proteinase 3; IVIg: Intravenous Immunoglobulins; n.obs: number of

observed cases.

Table 2. Rates of acute arterial and venous thromboembolic events standardized to the

Bruneck cohort.

	Bruneck cohort, rate per 1000 person-years	EGPA cohort, observed no. of events	EGPA cohort, expected no. of events	SER (95% CI)
All thromboembolic events				
Age category				
<55 years	5.7 (3.5-9.2)	25	8.0	3.12 (2.11-4.62)
55 to <65 years	7.4 (5.3-10.4)	23	7.1	3.24 (2.16-4.88)
65 to <75 years	16.5 (13.3-20.5)	13	12.5	1.04 (0.60-1.78)
≥75 years	34.4 (29.3-40.4)	14	8.2	1.72 (1.02-2.90)
Overall		75	35.8	2.10 (1.67-2.63) P<0.001
Arterial events				
Age category				
<55 years	2.5 (1.2-5.2)	17	3.5	4.86 (3.02-7.81)
55 to <65 years	5.8 (4.0-8.6)	13	5.6	2.33 (1.35-4.01)
65 to <75 years	13.3 (10.5-16.9)	5	10.1	0.49 (0.21-1.19)
≥75 years	29.3 (24.6-34.9)	8	6.9	1.15 (0.58-2.31)
Overall		43	26.1	1.64 (1.22-2.22) P<0.001
Venous events				
Age category				
<55 years	3.2 (1.7-6.1)	8	4.5	1.78 (0.89-3.55)
55 to <65 years	1.6 (0.7-3.3)	10	1.5	6.65 (3.58-12.36)
65 to <75 years	3.2 (1.9-5.2)	8	2.4	3.31 (1.65-6.62)
≥75 years	5.1 (3.4-7.8)	6	1.2	4.95 (2.23-11.03)
Overall		32	9.6	3.32 (2.35-4.70) P<0.001

CI: confidence interval; SER standardized event ratio.

FIGURES

Figure 1. Time of occurrence of acute arterial and venous thromboembolic events before and after the diagnosis EGPA.

Events with missing data (i.e. type or timing of the event) are not reported.

EGPA: Eosinophilic Granulomatosis with Polyangiitis

Figure 2. Kaplan-Meier curve of the occurrence of overall, arterial and venous thromboembolic events in the study cohort.

AVTE: arterial and venous thromboembolic events

Figure 3. Adjusted risks of acute arterial and venous thromboembolic events (AVTE), according **a)** to demographic, clinical and EGPA-related features, and **b)** to specific EGPA manifestations.

Risks are adjusted for age, sex, previous AVTE, ANCA, BVAS, eosinophils, and presence of cardiovascular risk factors.

ANCA: Anti-Neutrophil Cytoplasmic Antibody; AVTE: arterial and venous thromboembolic events; BVAS: Birmingham Vasculitis Activity Score; CV: Cardiovascular; FFS: Five-Factor Score.